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protein-coupled receptor constitutive activity, with this activity speciﬁcally blocked by inverse agonists, a
particular class of ligands often previously characterised as merely antagonists. The melanocortin
receptors are highly unusual because their physiological activity is mediated not by a single ligand but
by a number of endogenous peptide ligands, with the ability to exhibit agonist, antagonist or potentially
inverse agonist behaviour. It remains more contentious to what extent the demonstrable constitutive
activity of melanocortin receptors, particularly those expressed within the central nervous system, has in
(patho)physiological processes. This review examines evidence from animal and laboratory based
studies, focussing particularly upon peripherally expressed melanocortin-1 receptors and centrally
expressed melanocortin-4 receptors, to consider how recent insights into both receptor structure itself
and the molecules know to play a role in melanocortin signalling continue to shape our understanding of
melanocortin biology.
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1.1. The concept of constitutive activation
The idea that a receptor can produce signal without agonist
intervention and that several antagonists can be ‘active’ inB.V. Open access under CC BY license. repressing such spontaneous activity is contained in the concept
of “negative efﬁcacy” or “inverse agonism” (Fig. 1). Since the ﬁrst
report by Costa and Herz that δ-opioid receptors can be active in
the absence of an agonist (Costa and Herz, 1989), an increasing
number of G protein coupled receptors have been shown to
exhibit spontaneous, constitutive activity in vitro that can be
reduced by inverse agonist ligands. These include the β2-adreno-
ceptor, the 5-hydroxytryptamine 5-HT2C receptor and the brady-
kinin β2 receptor (Costa and Cotecchia, 2005). Indeed drugs with
β-adrenoceptor inverse agonist properties have been used in a
successful, clinically-relevant manner(Parra and Bond, 2007).Con-
stitutive activity is also a frequent outcome of G protein coupled
Fig. 1. Pharmacology of inverse agonism. Ligand behaviour in receptor systems
with constitutive activity (based on Parra and Bond, 2007).
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receptors exhibiting unregulated and ligand-independent activity,
thereby causing autonomous, pathological hormonal secretion.
Examples include the thyroid-stimulating hormone receptor (caus-
ing hyperthyroidism), the luteinizing hormone receptor (causing
precocious puberty), the parathyroid hormone receptor (causing
dwarﬁsm) and the calcium-sensing receptor (causing hypocalcae-
mia and hypercalciuria)(reviewed in (Parnot et al., 2002)).
Crucial as this information is for patients and families suffering
with these conditions, study of these mutations has also contrib-
uted to novel insights underpining current understanding of
agonist-driven receptor activation. In an erudite review by Costa
and Cotecchia, the hypothesis is rehearsed that rather than an
agonist being the prime mover of activity, it is the instrinsic, native
receptor structure which is the driver (Costa and Cotecchia, 2005).
Constraining intramolecular interactions keep the ligand-free
receptor silent with the “the key mission” of an agonist being to
relieve the receptor from these intrinsic constraints.
Evidence for such an idea comes from studies such as those
carried out over 20 years ago by Kjelsberg et al. (1992). By
substituting any one of the 19 other amino acids for alanine at
position 293 in the α1 β-adrenergic receptor, they were able to
produce a receptor that had constitutive activation. That all
possible mutations at this particular site resulted in increased
activity suggested that this region functions to constrain the G-
protein coupling of the receptor, a constraint which is normally
relieved by agonist occupancy.
This concept of a speciﬁc intramolecular region having a role in
regulating the tonic activity state of a receptor and its relevance to
melancortin biology will be revisited in Section 3.1.
1.2. Melanocortin signalling; multiple receptors, multiple ligands.
Melanocortin peptide effects are mediated through a family of
ﬁve melanocortin receptors, which are homologous seven-
transmembrane domain G-protein coupled receptors with differ-
ential anatomical expression and function (reviewed in (Cone,
2006)).Thus melanocortin-1 receptors are expressed on melano-
cytes having a role in pigmentation while melanocortin-2 recep-
tors are found on the adrenal cortex with a critical role in
adrenocortical steroidogenesis. Melanocortin-3 receptors are more
widely expressed within the central nervous system and gastro-
intestinal and renal tracts and have a role in energy homeostasis
and partitioning, as well as potential role in sodium balance.
Melanocortin-4 receptor expression is essentially restricted to
the brain and spinal cord and had a key role energy homeostasis
and autonomic function such as control of blood pressure and
erectile function. Finally melanocortin-4 receptors are expressed
at a low level in a range of tissues across the body but areparticularly enriched in exocrine cells where it has a role in the
synthesis and secretion of exocrine products.
Much is known about their molecular signalling mechanisms.
For example, melanocortin-4 receptors have long been known to
regulate intracellular concentrations of cyclic 3, 5-adenosine
monophosphate (cAMP) by increasing adenylyl cyclase (AC) activ-
ity through Gs proteins and afterwards enhancing activity of
protein kinase A (PKA)(Gantz et al., 1993). However, understanding
the melanocortin receptors is made more complex because their
activity is mediated by a series of endogenous peptide ligands,
each with different propensities to act agonistically or antagonis-
tically at the receptor. Further, each receptor has a different ligand
binding preference. Several of these agonist ligands arise from the
pro-opiomelanocortin (POMC) precursor peptide which is pro-
cessed by a series of enzymatic steps to produce a range of smaller
peptides, including the melanocortins (Cone, 2006). In contrast,
the best characterised antagonist is Agouti- related peptide
(AgRP). AgRP is exclusively expressed in a group of neurons in
the arcuate nucleus of the mediobasal hypothalamus and, like
POMC, AgRP is also post-translationally cleaved with AgRP83132
being the predominant secreted peptide with most antagonist
activity at melanocortin-4 receptor (Creemers et al., 2006). How-
ever, as data discussed below reveals, this canonical model of
agonist–antagonist competition at a receptor is no longer a wholly
valid model, likely being an oversimpliﬁcation of a system with far
more degrees of subtlety.2. Melanocortin-1 receptors-evidence from the periphery
Mammalian skin and hair pigmentation are complex, polygenic
traits (Barsh, 1996). However, classic genetic studies of mouse coat
colouration have revealed that activity at melanocortin-1 recep-
tors play a crucial role in melanogenesis and in determining the
balance between phaeomelanin (yellow) over eumelanin (brown/
black) pigment production. For example, work done by Cone and
colleagues has shown that mutations within the extension locus
(E) encoding the melanocortin-1 receptors are responsible for
distinct phenotypic appearance (Robbins et al., 1993). Thus, the
recessive yellow allele (e) contains a frameshift mutation that
produces a prematurely terminated, non-functioning receptor and
an animal with a yellow coat, while the sombre allele (Eso-3J)
contains a point mutation that produces a constitutively activated
receptor and a uniform jet black fur(Robbins et al., 1993). In
humans too, recessive mutations within MC1R that render the
receptor unresponsive to melanocortin stimulation result in a red
hair phenotype (Rees, 2003).
The activity of melanocortin-1 receptors can be inﬂuenced by
the surrounding ligand milieu. Elevated systemic levels of mela-
nocortins derived from POMC synthesised in the pituitary seen, for
example, in response to primary adrenal failure/removal, stimu-
lates skin pigmentation(Banasiak and Malek, 2007), while the ﬁrst
reports of POMC deﬁciency in humans were characterised by red
hair and pale skin (Krude et al., 1998, 1999; Krude and Gruters,
2000).
Murine skin is also a source of another ligand, the agouti
protein, the product of the agouti locus A. Agouti protein is
produced in dermal papilla cells and acts in a paracrine manner
to promote phaeomelanin over eumelanin pigment production
(Poole and Silvers, 1976). In keeping with this role, recessive loss of
function mutation in agouti (a) results in black fur. Agouti has a
key role in the coat colouration typical of wild type mice, when a
transient switch driven by agouti protein during hair development
temporally favours eumelanin synthesis and produces a subapical
band of yellow in an otherwise dark hair (Vrieling et al., 1994).
A.P. Coll / European Journal of Pharmacology 719 (2013) 202–207204However, clear phenotypic data from a number of mice lines
with global loss of POMC indicate that the activity at melanocortin-
1 receptors is more complex. A strong line of evidence comes from
studying mice carrying the spontaneous arising dominant yellow
allele (Ay). Ay is the result of a genomic deletion that fuses the
sequence encoding Agouti to the promoter of Raly, a nearby gene
that is constitutively active (Ollmann et al., 1998). As a result, Agouti
is ubiquitously expressed at high level. The coat colour of these
mice is a blond yellow, much paler than that seen inMc1r null mice
and thereby indicating that Agouti is doing more than simply
antagonising melanocortin at MC1R. Further, if the activity outcome
at melanocortin-1 receptors were just decided by the agonist-
antagonist playoff betweenmelanocortin and Agouti, in the absence
of all POMC derived ligand, one might predict a yellow mouse. Yet
both the ﬁrst reported Pomc null mouse generated by Hochgesch-
wender on a 1291;129S6 white-bellied agouti genetic back-
ground (Aw/Aw)(Yaswen et al., 1999) and the Pomc / mouse
characterised in our laboratory ( 129S6;129S2 background)(Challis
et al., 2004) had only modest alteration in coat colour. There was a
lighter yellow tint on the hairs that was readily discernible to the
naked eye but this appearance was not the global yellow coat seen
with the recessive yellow allele. Furthermore, when Smart and Low
backcrossed the null Pomc allele from Hochgeschwender′s mouse
onto the C57BL/6J nonagouti (a/a) genetic background (Smart and
Low, 2003), within two generations the black fur in these animals
was indistinguishable from wild type controls. Detailed phenotypic
analysis by Slominski et al. of the components of the melanogenic
system clearly showed preservation of eumelanin hair pigmenta-
tion in this nonagouti (a/a) background despite a total absence of
melanocortin ligand, in keeping with a high basal activity of
melanocortin-1 receptor (Slominski et al., 2005).
How then to interpret the red hair and pale skin of the POMC
null humans? Following on from their ﬁrst report of two children
with POMC deﬁciency (Krude et al., 1998), Gruters and colleagues
reported a further 3 children of Northern European Ancestry
(Krude et al., 2003). Again, the hair colour of all three children
was red or red–brown and the skin was pale, in contrast to other
members of their family. Intriguingly, in two of the patients their
hair colour darkened to brown in the second and third year of life.
Farooqi has also reported a case of complete POMC deﬁciency in a
proband of Turkish origin where, on initial examination, the
patient did not have red hair, rather brown hair with dark red
roots(Farooqi et al., 2006). The patient also had an obese sibling
who carried the same mutation and was reported to have had the
same hair colouring. That these latter patients had, at least
partially, retained dark, eumelanin-rich hair can be taken as
evidence that as in the mouse, hair and skin colouration in
humans is also a complex, polygenic trait with no absolute
dependent on the presence of melanocortins. Yet it is worthwhile
noting that there may also be intrinsic differences between human
and murine melanocortin-1 receptors. Using a range of transgenic
mice, Jackson and colleagues sought to make a direct comparison
within a physiological context of the receptors from both species
(Jackson et al., 2007). They demonstrated that mice with endo-
genous Mc1r but which lack both POMC and Agouti were indis-
tinguishable from mice with an intact Pomc gene, indicative of
considerable ligand-independent activity within this mouse recep-
tor. However, if the mouse receptor was replaced with human
MC1R again in a mouse lacking both POMC and Agouti, then the
mice were almost completely yellow. Thus it appears that in this
in vivo setting, human melanocortin-1 receptors lack sufﬁcient
ligand-independent signalling to produce signiﬁcant eumelanin.
So, can a wild type melanocortin-1 receptors exhibit constitu-
tive activity? Yes, it can. Does it always do so in all species to the
same degee? Probably not. All these data go on to serve again as
reminder that, as with so many other systems, melanocortinergicsignalling is subject to genetic and biochemical factors that
interact in a temporal and spatial manner rather than in any
simplistic linear fashion.3. Evidence from melanocortin 4 receptors
3.1. In vitro
Unequivocal data from a number of studies show that AgRP can
impact upon food intake and body weight through antagonism of
central melanocortin receptors (Cone, 2005). However, evidence
for AgRP acting as an inverse agonist has emerged from a number
of in vitro studies. Nijenhuis et al. transfected human MC4r into
MCB16/G4F cells, a mouse melanoma line with no endogenous
expression of melanocortin receptor (Nijenhuis et al., 2001). They
reported adenylyl cyclase activity as percentage of [3H]ATP con-
verted to [3H]cAMP. While basal adenylyl cyclase activity was not
signiﬁcantly different in three clones expressing 1.6104,
5.0104, and 5.6104 receptors per cell, (% cAMP around 0.5%)
in a fourth clone expressing 23104 receptors per cell there was a
small but signiﬁcant increase in % cAMP to 1.26%. Further, they
showed that treatment of the cells with AgRP83–132 could dose-
dependently suppress this basal adenylate cyclase activity by up to
60%, consistent with an inverse agonist activity at a receptor
displaying constitutive activity. Similarly, in a human embryonic
kidney (HEK-293) cell line over-expressing a constitutively active
mutant murine melanocortin-4 receptor with increased basal
activity, Haskell-Luevano and Monck demonstrated that signalling
could be dose-dependently suppressed by AgRP, once again
supporting the hypothesis that AgRP has inverse agonist activity
(Haskell-Luevano and Monck, 2001). Building upon these ﬁndings,
Srinivasan and colleagues undertook a series of in vitro experi-
ments to try and locate the structural determinants required for
this putative constitutive activity (Srinivasan et al., 2004). By
studying functional defects in naturally occurring melanocortin-4
receptor mutations found in obese patients, they hoped to be able
to gain insights into how melanocortin-4 receptor constitutive
activity might impact upon the maintenance of energy balance.
The work focused particularly upon a class of point mutations
within the extracellular N-terminal domain which did not impair
the response to α-MSH ligand action. Intriguingly in both transient
and stable cell transfections, when compared to wild type ligand,
these N terminal mutants exhibited a signiﬁcant decrease in
constitutive activity. They went on to look at the action of a mutant
melanocortin-4 receptor in which the ﬁrst 24 amino acids were
deleted. Taking care to add a signal peptide to ensure the receptor
was still expressed on the cell surface, their data indicated the loss
of this N terminal portion abolished basal activity without affecting
the response to α-MSH stimulation. More recently the same group
have gone on to further test the hypothesis that this N-terminal
region may be viewed as a tethered intramolecular ligand (Ersoy
et al., 2012). Ersoy et al. found that a peptide mimicking amino acids
2–26 of the melanocortin-4 receptor could restore the diminished
level of constitutive activity of a melanocortin-4 receptor missing
the ﬁrst N terminal amino acids back to that seen in wild type
receptor. In addition, not only did they report that the inverse
agonism by AgRP was due to its speciﬁc inhibition of the N terminal
induced self-activation but that through data generated by systema-
tic alanine scanning mutagenesis, concluded the activity brought
about by the N terminal domain relied on different key residues in
the transmembrane region to those necessary for αMSH activation
(Fig. 2).
Such a dichotomous situation lead this group to suggest that
the prime mode of activity modulation may not be wholly driven
by activation by diffusible ligand, but rather be based around
Fig. 2. Potential activation of melancortin 4 receptor. Two distinct sites of activation
may exist, one for soluble ligane (MSH) and a second for tethered intramolecular
ligand (N terminus), with both inhibited by AgRP. (based on Ersoy et al, 2012).
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activation and inverse agonism, echoing the reﬂections of previous
commentators (Costa and Cotecchia, 2005).
Yet while not to negate wholly the messages coming from
in vitro studies, some important caveats need to be borne in mind.
There is a need for caution when conﬂating data from bench top
laboratory studies and pathological mutations with physiological
role. In the quest to maintain a tractable environment in which
one has the best chance to get an answer to a question, one is always
open to the charge that the artiﬁcial, controlled model systems
created are too free from the vagaries of “endogenous life” and the
ﬂuxes apparent in associated regulatory and signalling pathway. This
alteration in critical components of the cellular background may
engender situations some way removed from that which is (patho)
physiologically relevant, changing, for example, the balance in
conformational receptors states into one where the ‘constitutively
active’ state is favoured in a far higher proportion than that seen
in vivo.
This issue was clearly recognised in one of the early reports
investigating how mutations in MC4R might result in obesity
(Vaisse et al., 2000). Froguel's group had identiﬁed in a patient
with morbid obesity (weight 145 kg, body mass index 59 kg/m2) a
mutation Leu250Gln not found in over 360 controls. Unexpectedly,
in a cell based assay based around the receptors ability to activate
expression of a cAMP-induced luciferase fusion gene, this muta-
tion not only showed a major increase in basal acitivty but also
was fully active by α-MSH. The authors acknowledge that this
apparent constitutive activation may not accurately represent in vivo
behaviour, with the ability to further determine if this mutation was
in any way causative hampered by the lack of clinical or genotypic
data for the parents of the proband.
More recently in their recent review of melanocortin-4 recep-
tor signalling, Breit et al. (2011) also correctly refer to the
“intertwining molecular mechanisms” through which the central
melanocortin system operates and point out that melanocortin-4
receptor is able to functionally engage with a range of G proteins
other than Gs, with cellular context, receptor expression level and
alternate active receptor conformation all contributing to the
variation in G protein coupling.
3.2. In vivo
Can animal model systems help progress our understanding?
Based on the hypothesis that constitutive melanocortin-4 receptor
activity in the brain would defend against increased food intake
and body weight gain, Vaisse predicted that mutant mice deﬁcient
in both POMC and AgRP would be less obese than mice deﬁcient
only in POMC (Srinivasan et al., 2004). Certainly, data from studiesby Low indicating that AgRP given to neuronal-speciﬁc POMC-
deﬁcient mice caused a delayed but persistent action on energy
balance had already lent in vivo support to the notion of AgRP
having an inverse agonist action in the absence of endogenous
agonists (Tolle and Low, 2008). Our laboratory reported a novel
mouse model lacking both Pomc and Agrp (Corander et al., 2011).
To our surprise, the phenotype of these mice resembled that of
mice lacking Pomc alone, displaying near identical levels of hyper-
phagia and obesity. Both mice were glucocorticoid-deﬁcient from
lack of adrenocorticotropin action at melanocortin-2 receptor but
again the effect of corticosterone supplementation was indis-
tinguishable between Pomc / /Agrp / mice and Pomc / mice
(Corander et al., 2011), arguing against AgRP having a role in the
exacerbation of hyperphagia seen in corticosterone – treated Pomc
null mice. We also undertook a series of studies delivering peptide
directly into the lateral ventricle of mice lack both Pomc and Agrp.
As expected NDP-α-MSH acted as a potent melanocortin agonist
(decreased food intake and body weight) that could be readily
antagonised by co-administration of AgRP. However, when these
mice received AgRP alone there was no effect on energy balance, at
least when assessed by changes in food intake, body weight and
relevant transcriptional proﬁling in brown adipose. These data
argue against there being constitutive activity of the MCR4 in vivo
and against AgRP having an inverse agonist activity at melanocortin
receptors. However, like all models there are important features
inherent within the system that require consideration. To undertake
the stereotactic surgery necessary for peptide injection, the mice
required corticosterone supplementation. It may be that such
corticosterone treatment rendered the mice so markedly hyperpha-
gia that any further increase in food intake brought about by inverse
agonist activity could not have been detected by the employed
methodology. Furthermore, bolus injection into the lateral ventricle
may have been too crude a tool by which to dissect subtle, region-
speciﬁc pharmacological differences in activities of melanocortin-4
receptors. Just as melanocortin-4 receptors in the paraventricular
nucleus of the hypothalamus appear to control food intake while
melanocortin-4 receptors elsewhere control energy expenditure
(Balthasar et al., 2005), it may be that a degree of regional speciﬁcity
extends also to the activity of AgRP, it being an antagonist at some
but an inverse agonist at other sites. Finally, just as Jackson showed
with melanocortin-1 receptor (Jackson et al., 2007), it may be that
these mouse models are not be able to reveal the whole story about
the activity of melanocortin-4 receptor in their natural environment
and that are some important species difference between human
and mouse receptors, in terms of their intrinsic sensitivity and their
expression levels.4. Novel roles for established players.
To add to the complexity, new roles to continue to be ascribed
to melanocortin-relevant molecules. Receptor endocytosis, the
ligand promoted translocation of a receptor from the plasma
membrane into the cell interior, is an important regulatory step
affecting most G-protein coupled receptors. It may be that in
addition to its interactions with ligand, soluble or otherwise, AgRP
is also able to induce receptor endocytosis. Using data from HEK
293 and Cos 7 lines with perturbation of β arrestin by both over-
expression and siRNA inhibition, Breit and colleagues have
reported that β arrestins involved in MCR endocytosis are induced
by the AgRP (Breit et al., 2006). Further, Agrp-induced melano-
cortin-4 receptor endocytosis can be observed in GT1-1 cells, a cell
line derived from murine hypothalamic neurons endogenously
expressing Mc4r, perhaps pointing to the physiological relevance
of AgRP-promoted receptor endocytosis. These data give rise to the
tantalising hypothesis that AgRP had a duality to its controlling
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a slower-acting effect of temporarily reducing the amount of
melanocortin-4 receptors located at the plasma membrane.
Reports from Mountjoy's group on human melanocortin recep-
tor accessory protein has highlighted that this molecule, whose
ability to facilitate function cell surface expression of melanocortin-
2 receptor is well characterised, appears also to be able to increase
melanocortin-4 receptor constitutive activation(Kay et al., 2013a,
2013b). In a series of experiments utilising HEK293 cells, they were
able to show that MRAPα isoform caused a signiﬁcant (25%) increase
in baseline coupling of transiently transfected melanocortin-4 recep-
tor and adenylyl cyclase when compare to transient expression of
melanocortin-4 receptor alone. Intriguingly, they speculate that this
might be through differential N-linked glycosylation at asparagines
residues within the same N terminal region previously extensively
characterised by the Vaisse laboratory.5. Discussion
In answer to the question as to the ability to demonstrate constitu-
tive activity at melanocortin receptors in vitro, the response is a
deﬁnitive yes. However, asking the same question about in vivo activity
requires a more considered answer. The challenge always with
melanocortin biology is that the receptors and their activity do not
sit readily into a simple linear path but are dependent upon, interact
with and signal through a whole cast of related molecules. This is
particularly the case with central melanocortin molecules and as
knowledge about the high degree of interconnectivity of hypothalamic
structure increases (Yeo and Heisler, 2012), it seems ever more
challenging to mimic the correct environment in vitro, nevermind
directly studying the activity of the receptor in its original neuronal
context.
Reviewing the role of AgRP after our report that mice lacking
both Pomc and Agrp were indistinguishable from Pomc null mice,
Low commented that it was probably sensible to “remain agnostic”
when consider whether AgRP is a physiologically relevant inverse
agonist (Low, 2011) and on the evidence still to date, this seems to
be a wise standpoint.
However, it may well be that in the coming years, more
compelling evidence will accrue. This author is aware of at least
one developing genetic study of humans who appear to be well
but constitutionally lean and it is tempting to speculate that
within this population there may be individuals with mutation
within MC4R whose basal activity causes a lean phenotype.
Studying such mutations if or when they arise will require using
a range of in vitro platform as well as animal models engineered to
carrying the same mutation, potentially even in with human
receptor in place of the endogenous mouse counterpart.
In Alice in Wonderland, Carroll give a vivid description of the
Caucus Race, an ill-deﬁned event run to help a disparate collection
of animals dry off (Carroll, 2006). Without constraint or order, the
ﬁnal result of the contest seems impossible to fathom and leads
the Dodo to declare that the only possible result is that “Everybody
has won, and all must have prizes.” Written to gently mock the lack
of clarity and decisiveness of one of the political system of the day,
but also perhaps relevant to the question leading this review. Each
of the studies reviewed has merit and worth, but none are wholly
beyond reproach. The challenge remains to further deﬁne the
environment within which melanocortin signalling occurs. Until
we know all the rules and players, it may remain impossible to
come to a ﬁnite answer. However, once these become clear,
subsequent data may then lead us to reconsider and reﬁne our
benchmarks of basal versus stimulated activity.References
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